These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 2908050)

  • 21. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does neuroleptic blocking of dopamine receptors continue after chronic treatment?
    Belmaker RH; Dasberg H; Ebstein RP
    Prog Biochem Pharmacol; 1980; 16():109-18. PubMed ID: 6108567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2 and muscarinic receptor binding characteristics in rat brain after withdrawal of subchronic fluphenazine and sulpiride treatment.
    Hietala J; Syvälahti E; Röyttä M
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):247-58. PubMed ID: 2526352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex.
    Meller E; Bohmaker K; Rosengarten H; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Sep; 37(3):323-32. PubMed ID: 7178646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
    Stockmeier CA; DiCarlo JJ; Zhang Y; Thompson P; Meltzer HY
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1374-84. PubMed ID: 8103793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
    Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
    Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
    Nakajima T; Iwata K
    Mol Pharmacol; 1984 Nov; 26(3):430-8. PubMed ID: 6149457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
    Prasad C; Spahn SA; Ikegami H
    Biochem Biophys Res Commun; 1989 Feb; 159(1):48-52. PubMed ID: 2522303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
    Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive changes in brain dopamine function as a result of neuroleptic treatment.
    Jenner P; Marsden CD
    Adv Neurol; 1988; 49():417-31. PubMed ID: 2894127
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacology of antipsychotic drugs.
    Borison RL
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):25-8. PubMed ID: 2858475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of striatal dopamine D2 receptor acquisition following prenatal neuroleptic exposure.
    Schmidt MH; Lee T
    Psychiatry Res; 1991 Mar; 36(3):319-28. PubMed ID: 1676523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic neuroleptic treatment increases D-2 but not D-1 receptors in rat striatum.
    MacKenzie RG; Zigmond MJ
    Eur J Pharmacol; 1985 Jul; 113(2):159-65. PubMed ID: 2864265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Are the antipsychotic and side-effects of neuroleptics imperfectly known?].
    Schulz P
    Biomed Pharmacother; 1987; 41(1):31-3. PubMed ID: 2886159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide.
    Tecott LH; Kwong LL; Uhr S; Peroutka SJ
    Biol Psychiatry; 1986 Oct; 21(12):1114-22. PubMed ID: 2428411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of chronic administration of haloperidol (intermittently) and haloperidol-decanoate (continuously) on D2 dopamine and muscarinic cholinergic receptors and on carbachol-stimulated phosphoinositide hydrolysis in the rat striatum.
    Akiyama K; Sato M; Yamada N; Otsuki S
    Jpn J Psychiatry Neurol; 1987 Jun; 41(2):311-20. PubMed ID: 2830427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats.
    See RE; Toga AW; Ellison G
    J Neural Transm Gen Sect; 1990; 82(2):93-109. PubMed ID: 1977417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with antipsychotics does not alter the phosphoinositide response to muscarinic or D2 dopaminergic agonists in rat striatum.
    Rubinstein JE; Hitzemann RJ; Ashby CR; Wang RY
    Brain Res; 1989 Sep; 496(1-2):385-8. PubMed ID: 2572294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.